These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12111907)

  • 1. Early selection in a randomized phase II clinical trial.
    Steinberg SM; Venzon DJ
    Stat Med; 2002 Jun; 21(12):1711-26. PubMed ID: 12111907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trials with a prospective control.
    Jung SH
    Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A three-outcome design for randomized comparative phase II clinical trials.
    Hong S; Wang Y
    Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal designs for two-arm, phase II clinical trial design with multiple constraints.
    Mayo MS; Mahnken JD; Soong SJ
    J Biopharm Stat; 2010 Jan; 20(1):106-24. PubMed ID: 20077252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A flexible design for multiple armed screening trials.
    Sargent DJ; Goldberg RM
    Stat Med; 2001 Apr; 20(7):1051-60. PubMed ID: 11276035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Picking the winners in a sea of plenty.
    Scher HI; Heller G
    Clin Cancer Res; 2002 Feb; 8(2):400-4. PubMed ID: 11839655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical Bayesian guidelines for phase IIB clinical trials.
    Thall PF; Simon R
    Biometrics; 1994 Jun; 50(2):337-49. PubMed ID: 7980801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial design for evaluation of novel targeted therapies.
    Farley J; Rose PG
    Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early stopping clinical trials of binomial response with an exact group sequential method.
    Zhao Z
    Stat Med; 2007 Apr; 26(8):1724-9. PubMed ID: 17206748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
    Zhang Y; Mietlowski W; Chen B; Wang Y
    J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient selection for phase II trials.
    Sonpavde G; Galsky MD; Hutson TE; Von Hoff DD
    Am J Clin Oncol; 2009 Apr; 32(2):216-9. PubMed ID: 19346816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.